Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

CAR-hematotox score for predicting outcomes among myeloma patients receiving BCMA targeting CART constructs (ide-cel and cilta-cel)

View Full Paper
Ask AI
Bookmark
Share

Authors

ANAjay K. NookaNJNisha S. Joseph

Discussion

Loading...

Member takes

Overview

Evaluation reveals CAR-HEMATOTOX score predicts 100- and 365-day mortality in myeloma patients, indicating its potential value as a biomarker.

Key Points

  • Mortality at day 100 was significantly higher for patients with high CAR-HEMATOTOX score at 11.8% compared to 2.2%.
  • This study included 247 myeloma patients treated with BCMA-targeting CAR constructs, yielding critical insights on risk stratification.
  • Analysis identified key biomarkers such as ferritin and immunomodulatory agents impacting overall survival and progression-free survival.
  • Potential for refining CAR-HEMATOTOX score to improve prediction accuracy for myeloma treatment outcomes is highlighted.

Cite This Study

Nooka et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236daa3https://doi.org/10.1182/blood-2025-4078
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy2025
  2. 2The prognostic value of CAR-hematox in predicting toxic events in patients with relapsed refractory B cell lymphoma receiving 7x19 CAR-T treatment2025
  3. 3Evaluating the CAR-hematotox score in patients with refractory-relapsed multiple myeloma treated with bispecific T-cell engager therapy2025
  4. 4CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia2025 · 4 citations
  5. 5Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma2025 · 2 citations